Suven Life Sciences share price has zoomed 5% and is presently trading at Rs 132.0.
Meanwhile, the BSE HEALTHCARE index is at 38,507.2 (up 0.9%).
Among the top gainers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (up 3.8%) and SUVEN PHARMACEUTICALS (up 3.7%).
Jubilant Pharmova (down 3.6%) and ASTRAZENECA PHARMA (down 1.7%) are among the top losers today.
Over the last one year, Suven Life Sciences has moved up from Rs 63.2 to Rs 132.0, registering a gain of Rs 68.7 (up 108.7%).
On the other hand, the BSE HEALTHCARE index has moved up from 26,342.4 to 38,507.2, registering a gain of 46.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 97.2%), Lupin (up 92.8%) and Cadila Healthcare (up 92.4%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 80,506.6 (down 0.1%).
The top losers among the BSE Sensex today are Reliance Ind. (down 3.4%) and Kotak Bank (down 3.3%). The most traded stocks in the BSE Sensex are Tata Steel and HDFC Bank.
In the meantime, NSE Nifty is at 24,515.9 (down 0.1%). Wipro and Reliance Ind. are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,795.1 to 80,506.6, registering a gain of 13,711.5 points (up 20.5%).
Suven Life Sciences net profit grew 4.0% YoY to Rs -265 million for the quarter ended March 2024, compared to a loss of Rs 276 million a year ago. Net sales declined 8.7% to Rs 24 million during the period as against Rs 26 million in January-March 2023.
For the year ended March 2024, Suven Life Sciences reported 11.2% increase in net profit to Rs -1,051 million compared to net loss of Rs 1,183 million during FY23. Revenue of the company fell 13.6% to Rs 117 million during FY24.
The current Price to earnings ratio of Suven Life Sciences, based on rolling 12 month earnings, stands at -27.4.
Equitymaster requests your view! Post a comment on "Suven Life Sciences Gains 5%; BSE HEALTHCARE Index Up 0.9%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!